Chao Zhao

Mr. Chao Zhao

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in Lung Cancer
Verified
Journal Article
Closed access
SZSha Zhao
Sha Zhao
GGGuanghui Gao
Guanghui Gao
WLWei Li
Wei Li
XLXuefei Li
Xuefei Li
CZChao Zhao
Chao Zhao
CZCaicun Zhou
Caicun Zhou

7 March 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
Tao JiangTao Jiang
Tao Jiang
XXXiaofeng Xu
Xiaofeng Xu
MQMeng Qiao
Meng Qiao
Xuefei LiXuefei Li
Xuefei Li
CZChao Zhao
Chao Zhao
CZCaicun Zhou
Caicun Zhou
CD73 is one of the critical component in the formation of immunosuppressive microenvironment in cancers. We aimed to provide an overview of the current status of CD73 expression and its relationship with clinicopathlogical features and prognosis in different cancers. PubMed, Web of Science, EMBASE and Cochrane library were searched to identify the relevant studies. CD73 expression level in distinct cancers and its relationship with clinicopathlogical characteristics and prognosis were investigated using online database. Meta-analyses were conducted using RevMan v5.0 and STATA v12.0. Fourteen publications with 2951 cases were included. The incidence of high CD73 expression was 0.50 (95% CI: 0.36–0.63). Data from Oncomine validated that median CD73 expression level in tumor tissues was markedly higher than that in normal tissues in most kinds of cancers except cecum adenocarcinoma and ovarian cancer (P < 0.05). High CD73 expression was significantly correlated with shorter overall survival (OS) in various cancers (high risk [HR] = 1.48; P < 0.05). Subgroup analysis using online database demonstrated that high CD73 expression was significantly correlated with poor OS in breast (HR = 1.23; P < 0.05) and ovarian cancer (HR = 1.14; P < 0.05), but favorable OS in lung (HR = 0.80; P < 0.05) and gastric cancer (HR = 0.71; P < 0.05). High CD73 expression was dramatically associated with lymph node metastases (OR = 2.61; P = 0.05). High CD73 expression was significantly associated with lymph node metastases and a promising prognostic factor in different types of cancers.

24 April 2019 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
XZXibin Zhuang
Xibin Zhuang
CZChao Zhao
Chao Zhao
JLJiayu Li
Jiayu Li
CSChunxia Su
Chunxia Su
XCXiaoxia Chen
Xiaoxia Chen
CZCaicun Zhou
Caicun Zhou
Background: Although oncogenic driver mutations were thought to be mutually exclusive in non‐small cell lung cancer (NSCLC), certain tumors harbor co‐occurring mutations and represent a rare molecular subtype. The evaluation of the clinical features and therapeutic response associated with this NSCLC subtype will be vital for understanding the heterogeneity of treatment response and improving the management of these patients.Methods: This retrospective study included 3774 samples from patients diagnosed with NSCLC. All samples were screened for EGFR, ALK, ROS1, KRAS, and BRAF mutation using the amplification‐refractory mutation system. The relationship between concomitant driver mutations and clinicopathologic characteristics, and patient clinical outcomes were evaluated.Results: Sixty‐three (1.7%) samples had more than one driver gene mutation. Among these, 43 were coalterations with an EGFR mutation, 20 with an ALK rearrangement, and eight with an ROS1 rearrangement. Except for ROS1 concomitant mutations that were more frequent in male patients (87.5%, P = 0.020), the clinicopathological features of the concomitant mutation patients were not significantly different from those harboring a single EGFR, ALK, or ROS1 mutation. Furthermore, first‐line EGFR‐TKI treatment did not significantly improve the progression‐free survival (PFS) of patients harboring EGFR concomitant mutation, compared to patients harboring a single EGFR mutation. However, for EGFR concomitant mutation patients, TKI therapy was more effective than chemotherapy (median PFS of 10.8 vs 5.2 months, P = 0.023). Lastly, KRAS mutations did not influence the EGFR‐TKI therapy treatment effect.Conclusion: In this study, concomitant mutations were found in 1.7% of the NSCLC. EGFR‐TKI therapy was more effective than chemotherapy for patients harboring EGFR concomitant mutation, and ROS1 concomitant mutations were more frequent in male patients. For patients harboring coalterations with an ALK or ROS1 rearrangement, we should be cautious when considering the therapeutic options.

1 February 2019 in Lung Cancer
Verified
Journal Article
Closed access
SZSha Zhao
Sha Zhao
XLXuefei Li
Xuefei Li
CZChao Zhao
Chao Zhao
TJTao Jiang
Tao Jiang
YJYijun Jia
Yijun Jia
CZCaicun Zhou
Caicun Zhou

1 September 2017 in Journal of Thoracic Disease
Verified
Journal Article
Open access
PDF file
TDTing Ding
Ting Ding
FZFei Zhou
Fei Zhou
XCXiaoxia Chen
Xiaoxia Chen
SZShijia Zhang
Shijia Zhang
YLYinan Liu
Yinan Liu
CZCaicun Zhou
Caicun Zhou
Background: Aimed to identify the benefit population from continuation of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), this study investigated the efficacy of continuation of EGFR-TKIs plus chemotherapy beyond the response evaluation criteria in solid tumors-progressive disease (RECIST-PD) according to different progression modes and T790M mutational status. Methods: From November 2009 to July 2015, 630 patients with advanced non-small cell lung cancer (NSCLC) receiving gefitinib as initial EGFR-TKI treatment were screened in Shanghai Pulmonary Hospital. A total of 170 patients with documented gradual or dramatic progression after gefitinib treatment who received chemotherapy alone or in combination with gefitinib were included. Post-RECIST-PD progression-free survival (PPFS) between continuation of gefitinib plus chemotherapy and chemotherapy alone was assessed. Results: The incidence of T790M mutation was 42.9% (63/147) in patients who got acquired resistance in this study. Median PPFS was 4.0 months [95% confidence interval (CI), 3.1–4.9 months] in the chemotherapy group and 5.0 months (95% CI, 3.6–6.4 months) in the combination group with a borderline statistical significance (P=0.071). Continuation of gefitinib plus chemotherapy resulted in a significant improvement in PPFS compared with chemotherapy alone in patients with EGFRT790M-negative tumors [median PPFS: 6.6 vs. 3.5 months, hazard ratio (HR) 0.50, 95% CI, 0.29–0.88; P=0.011], especially in pemetrexed-based chemotherapy (HR 0.45, 95% CI, 0.24–0.86; P=0.011). PPFS was similar in patients with EGFRT790M-positive tumors (median PPFS: 5.0 vs. 5.5 months, HR 0.80, 95% CI, 0.40–1.61; P=0.520) or EGFRT790M-unknown tumors (median PPFS: 2.0 vs. 3.0 months, HR 1.40, 95% CI, 0.69–2.81; P=0.323). Conclusions: Our study showed that continuous gefitinib plus chemotherapy, especially pemetrexed-based therapy, significantly improved PPFS in patients with EGFRT790M-negative tumors as compared with chemotherapy alone, suggesting that this subtype of patients may derive clinical benefit from continuation of gefitinib treatment beyond progression.

1 November 2019 in Lung Cancer
Verified
Journal Article
Closed access
YJYijun Jia
Yijun Jia
SZSha Zhao
Sha Zhao
TJTao Jiang
Tao Jiang
XLXuefei Li
Xuefei Li
CZChao Zhao
Chao Zhao
CZCaicun Zhou
Caicun Zhou